Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care

Group 1: Acquisition and Services - Quest Diagnostics has completed the acquisition of select clinical testing assets from Fresenius Medical Care's Spectra Laboratories, enhancing its ability to provide dialysis-related clinical testing to independent dialysis clinics [1] - Quest will also begin providing comprehensive dialysis-related laboratory services for Fresenius-operated dialysis centers, which serve approximately 200,000 patients annually, with the transition expected to be completed by early 2026 [2] Group 2: Operational Benefits - The arrangement allows dialysis clinics to benefit from Quest's clinical leadership and diagnostic innovation in chronic kidney disease services, with multiple Quest laboratories providing testing to nearby clinics, thus reducing transportation time and speeding up results reporting [3] - Quest aims to optimize its return on capital by performing testing during lower-volume daytime hours [3] Group 3: Industry Context - Chronic kidney disease affects about 35.5 million people, or 14% of the U.S. population, making it one of the most prevalent chronic diseases in the U.S. [4] - More than 800,000 people in the U.S. receive dialysis, which requires periodic lab testing to manage the disease and testing water for contaminants [4]